Feed aggregator

Pharma join together to achieve new standards in digital and patient innovation for clinical transformation

World Pharma News - Mon, 03/14/2022 - 13:00
17 - 19 May 2022, Virtual.
On May 17th , 500+ of pharma's clinical innovation will come together for the home of clinical collaboration, Reuters Events: Pharma Clinical 2022, to set new standards in digital and patient innovation for clinical transformation.

The catalyst for this has been the accelerated technological adoption in clinical trials, but a general feeling still that enough isn't being done for patients, failing to develop co-created, data-driven, standardised and accountable trial design.

Pfizer updates company position in Russia

World Pharma News - Mon, 03/14/2022 - 11:00
Pfizer Inc. (NYSE: PFE) Pfizer stands with the unified global community across the public, private and civil society sectors in opposition to the Russian war in Ukraine and the brutal situation it has created.

The international community has implemented unprecedented sanctions to Russia.

Mutations leading to omicron variant did not enable virus to fully escape immune system

World Pharma News - Fri, 03/11/2022 - 11:00
People who gained immunity - either through vaccination or exposure - against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen's omicron variant. That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response,

Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy

World Pharma News - Thu, 03/10/2022 - 13:00
Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.

Under the terms of the initial agreement, the Carisma Therapeutics manufacturing process will be transferred to the Novartis Cell Therapy Site in Morris Plains, U.S, starting in the coming days.

Stealth nanomedicines combat cancer and cut toxic effects of chemo

World Pharma News - Thu, 03/10/2022 - 11:00
Nanomedicines - typically drugs hidden within nanoscopic fatty membranes ('liposomes') - have potential to transform chemotherapy treatments, improving drug delivery and reducing toxic side effects for thousands of cancer patients every year.

Now, world first research conducted by the University of South Australia has identified that the frequently used chemotherapy drug (5-FU or Fluorouracil) is 100 per cent more effective at targeting tumours (rather than surrounding tissues) when administered using an optimised liposomal formulation.

COVID-19 beliefs influenced by politicians, not scientists, researchers suggest

World Pharma News - Wed, 03/09/2022 - 13:00
As COVID-19 upended societal norms when it swept through the United States in 2020, a second pandemic - or "infodemic" - was also on the rise. An analysis of Twitter users by researchers at the University of California, Davis, and University of Texas, Austin, suggests that Republican-identifying individuals who believe their local government has positive intentions are vulnerable to believing politically fueled COVID-19 misinformation.

Scientists identify possible new treatment for COVID-19

World Pharma News - Wed, 03/09/2022 - 11:00
Investigators at Cedars-Sinai have identified a potential new therapy for COVID-19: a biologic substance created by reengineered human skin cells.

Scientists found the substance stopped SARS-CoV-2, the virus that causes COVID-19, from reproducing itself and also protected infected cells when tested in human lung cells.

Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases

World Pharma News - Tue, 03/08/2022 - 13:00
Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

New strategy for COVID-19 prophylaxis

World Pharma News - Tue, 03/08/2022 - 11:00
SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. Researchers led by Prof. Dr. Gunther Hartmann from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn, in cooperation with other members of the cluster of excellence ImmunoSensation2 at the University of Bonn, have shown this in mice.

Statement on humanitarian aid in Ukraine

World Pharma News - Mon, 03/07/2022 - 13:00
Ugur Sahin, CEO and Co-Founder of BioNTech: "We at BioNTech are closely following the tragic situation in Ukraine and our thoughts are with everyone affected. As a company with employees from 60 countries, we know that diversity and community are stronger than pursuing single-sided interests. We join the call of the global community and urge those involved to return to peaceful coexistence in the region for the sake of all people.

AI-designed protein awakens silenced genes, one by one

World Pharma News - Mon, 03/07/2022 - 11:00
By combining CRISPR technology with a protein designed with artificial intelligence (AI), it is possible to awaken individual dormant genes by disabling the chemical “off switches” that silence them. Researchers from the University of Washington School of Medicine in Seattle describe this finding in the journal Cell Reports.

National science academies of the G7 states publish joint statement on the war in Ukraine

World Pharma News - Fri, 03/04/2022 - 13:00
The national science academies of the G7 states publish a joint statement on Russia's attack on Ukraine.

The science academies have been accompanying the annual meetings of the G7 states for more than 15 years. In the run-up to each summit, they address scientific agenda-related issues that require multilateral action.

AI helped protect businesses from COVID-19 risks

World Pharma News - Fri, 03/04/2022 - 11:00
A new study has found that artificial intelligence (AI) apps helped protect small and medium-sized businesses against many of the risks that emerged during the COVID-19 pandemic - yet only a quarter of small firms currently use them.

The research, undertaken by Anglia Ruskin University (ARU) and published in the journal Information Systems Frontiers, surveyed 317 small and medium sized firms based in London.

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

World Pharma News - Thu, 03/03/2022 - 13:00
The leading research-driven biopharmaceutical company Boehringer Ingelheim and precision medicine software company Lifebit Biotech, Ltd. (Lifebit) today announce partnership in which Lifebit will support Boehringer Ingelheim in building a scalable data, analytics, and infrastructure platform within its IT environment.

Blood pressure medication shows benefits treating Type 1 diabetes

World Pharma News - Thu, 03/03/2022 - 11:00
Use of the drug verapamil to treat Type 1 diabetes continues to show benefits lasting at least two years, researchers report in the journal Nature Communications. Patients taking the oral blood pressure medication not only required less daily insulin two years after first diagnosis of the disease, but also showed evidence of surprising immunomodulatory benefits.

Targeted enzymes destroy virus RNA

World Pharma News - Wed, 03/02/2022 - 23:17
A research team led by the Technical University of Munich (TUM) has successfully used specific enzymes to destroy the genetic information of SARS-CoV-2 directly after the virus penetrates the cell. The findings could serve as the basis for a therapy to treat COVID-19.

Our genome contains building instructions for proteins and other molecules. In order for these to be produced by the cell, a kind of transcript of these building instructions must first be created, which takes the form of so-called RNA molecules.

Roche announces donation of essential medicines to Ukraine

World Pharma News - Wed, 03/02/2022 - 11:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced an initial donation of essential medicines to Ukraine. Roche vehemently condemns the violent invasion of the country.

Roche is working diligently to support the country and people of Ukraine with medical products in accordance with Roche's overall mission and announced today that we are donating 150,000 packages of Rocephin, a critical antibiotic used to treat the symptoms of many kinds of bacterial infections and listed on the World Health Organization's list of essential medicines.

SMi's 22nd Annual Pain Therapeutics Conference

World Pharma News - Tue, 03/01/2022 - 13:00
4 - 5 May 2022, London, United Kingdom.
SMi's 22nd Pain Therapeutics Conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.

Booster critical as COVID-19 vaccine-induced antibodies wane in 6 months, don't protect against omicron

World Pharma News - Tue, 03/01/2022 - 11:00
A new study using serum from human blood samples suggests neutralizing antibody levels produced by two-dose mRNA vaccines against the original and early variants of the SARS-CoV-2 virus wane substantially over time, and offer essentially no protection against the omicron variant.

Fighting COVID-19 with milk?

World Pharma News - Mon, 02/28/2022 - 13:00
As the COVID-19 pandemic continues to claim lives around the world, dairy scientists may have a surprising role to play. In a new report published in the Journal of Dairy Science®, scientists from the University of Michigan (Ann Arbor, MI, USA) and Glanbia PLC Research and Development (Twin Falls, ID, USA) have collaborated to investigate the antiviral properties of cow milk protein against variants of SARS-CoV-2, the virus behind the illness.